These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19777211)

  • 1. The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.
    Gierten J; Ficker E; Bloehs R; Schweizer PA; Zitron E; Scholz E; Karle C; Katus HA; Thomas D
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):261-70. PubMed ID: 19777211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels.
    Staudacher K; Staudacher I; Ficker E; Seyler C; Gierten J; Kisselbach J; Rahm AK; Trappe K; Schweizer PA; Becker R; Katus HA; Thomas D
    Br J Pharmacol; 2011 Jul; 163(5):1099-110. PubMed ID: 21410455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.
    Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Oct; 385(10):1003-16. PubMed ID: 22790794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.
    Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
    Eur J Pharmacol; 2013 Dec; 721(1-3):237-48. PubMed ID: 24070813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and functional characterization of zebrafish K(2P)10.1 (TREK2) two-pore-domain K(+) channels.
    Gierten J; Hassel D; Schweizer PA; Becker R; Katus HA; Thomas D
    Biochim Biophys Acta; 2012 Jan; 1818(1):33-41. PubMed ID: 21963410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.
    Seyler C; Li J; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Feb; 724():51-7. PubMed ID: 24374008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
    Kiehn J; Thomas D; Karle CA; Schöls W; Kübler W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Mar; 359(3):212-9. PubMed ID: 10208308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.
    Seyler C; Schweizer PA; Zitron E; Katus HA; Thomas D
    Biochem Biophys Res Commun; 2014 Aug; 451(3):415-20. PubMed ID: 25108155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
    J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K
    Schmidt C; Wiedmann F; Gaubatz AR; Ratte A; Katus HA; Thomas D
    J Pharmacol Exp Ther; 2018 Jun; 365(3):614-623. PubMed ID: 29643254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein.
    Gierten J; Ficker E; Bloehs R; Schlömer K; Kathöfer S; Scholz E; Zitron E; Kiesecker C; Bauer A; Becker R; Katus HA; Karle CA; Thomas D
    Br J Pharmacol; 2008 Aug; 154(8):1680-90. PubMed ID: 18516069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac K
    Staudacher I; Seehausen S; Illg C; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Prog Biophys Mol Biol; 2019 Jul; 144():128-138. PubMed ID: 31182191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.
    Thomas D; Kathofer S; Zhang W; Wu K; Wimmer AB; Zitron E; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
    Br J Pharmacol; 2003 Nov; 140(5):996-1002. PubMed ID: 14517175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
    Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
    J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular electropharmacology of amiodarone.
    Kodama I; Kamiya K; Toyama J
    Cardiovasc Res; 1997 Jul; 35(1):13-29. PubMed ID: 9302343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of class III antiarrhythmic drugs on the Na(+)-activated K+ channels in guinea-pig ventricular cells.
    Mori K; Saito T; Masuda Y; Nakaya H
    Br J Pharmacol; 1996 Sep; 119(1):133-41. PubMed ID: 8872366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.
    Schmidt C; Wiedmann F; Zhou XB; Heijman J; Voigt N; Ratte A; Lang S; Kallenberger SM; Campana C; Weymann A; De Simone R; Szabo G; Ruhparwar A; Kallenbach K; Karck M; Ehrlich JR; Baczkó I; Borggrefe M; Ravens U; Dobrev D; Katus HA; Thomas D
    Eur Heart J; 2017 Jun; 38(22):1764-1774. PubMed ID: 28057773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the A293 (AVE1231) Binding Site in the Cardiac Two-Pore-Domain Potassium Channel TASK-1: a Common Low Affinity Antiarrhythmic Drug Binding Site.
    Wiedmann F; Kiper AK; Bedoya M; Ratte A; Rinné S; Kraft M; Waibel M; Anad P; Wenzel W; González W; Katus HA; Decher N; Schmidt C
    Cell Physiol Biochem; 2019; 52(5):1223-1235. PubMed ID: 31001961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure.
    Schmidt C; Wiedmann F; Langer C; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Heart Rhythm; 2014 Oct; 11(10):1798-805. PubMed ID: 24952150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.